Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Update

Bionano Genomics, Inc. (NASDAQ:BNGO) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 15,840,000 shares, a growth of 25.1% from the November 30th total of 12,660,000 shares. Currently, 15.6% of the company’s stock are sold short. Based on an average trading volume of 2,880,000 shares, the short-interest ratio is presently 5.5 days.

Bionano Genomics Stock Up 36.2 %

NASDAQ:BNGO opened at $0.29 on Tuesday. The firm has a market capitalization of $29.18 million, a price-to-earnings ratio of -0.12 and a beta of 2.28. The company has a quick ratio of 0.99, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. Bionano Genomics has a twelve month low of $0.19 and a twelve month high of $2.16. The stock’s 50 day moving average price is $0.25 and its two-hundred day moving average price is $0.43.

Hedge Funds Weigh In On Bionano Genomics

Institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC bought a new position in shares of Bionano Genomics in the 2nd quarter valued at about $1,138,000. Geode Capital Management LLC lifted its stake in Bionano Genomics by 47.3% in the 3rd quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after purchasing an additional 283,639 shares during the last quarter. GSA Capital Partners LLP bought a new position in Bionano Genomics during the third quarter worth about $46,000. Finally, Carret Asset Management LLC increased its position in Bionano Genomics by 89.0% during the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after buying an additional 40,055 shares during the last quarter. 11.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. LADENBURG THALM/SH SH lowered shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Friday, November 15th. BTIG Research downgraded shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 10th.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.